Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antagonisté endotelinového receptoru A chemie MeSH
- antihypertenziva chemie MeSH
- atrasentan MeSH
- hypertenze patofyziologie MeSH
- kaptopril chemie MeSH
- krevní tlak fyziologie MeSH
- krmivo pro zvířata MeSH
- krysa rodu Rattus MeSH
- kuchyňská sůl farmakologie MeSH
- NG-nitroargininmethylester chemie MeSH
- nifedipin chemie MeSH
- oxid dusnatý metabolismus MeSH
- pentoliniumtartrát chemie MeSH
- potkani Sprague-Dawley MeSH
- potkani transgenní MeSH
- pyrrolidiny terapeutické užití MeSH
- renin-angiotensin systém účinky léků MeSH
- renin genetika MeSH
- sympatický nervový systém patofyziologie MeSH
- synthasa oxidu dusnatého metabolismus MeSH
- vápník chemie metabolismus MeSH
- vápníkové kanály - typ L metabolismus MeSH
- vazodilatace účinky léků MeSH
- vazokonstrikce účinky léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antagonisté endotelinového receptoru A MeSH
- antihypertenziva MeSH
- atrasentan MeSH
- kaptopril MeSH
- kuchyňská sůl MeSH
- NG-nitroargininmethylester MeSH
- nifedipin MeSH
- oxid dusnatý MeSH
- pentoliniumtartrát MeSH
- pyrrolidiny MeSH
- Ren2 protein, rat MeSH Prohlížeč
- renin MeSH
- synthasa oxidu dusnatého MeSH
- vápník MeSH
- vápníkové kanály - typ L MeSH
BACKGROUND: Our previous experiments demonstrated that selective endothelin A (ETA) receptor blockade had antihypertensive effects in Ren-2 transgenic rats (TGRs), but the mechanisms responsible for this change of blood pressure (BP) have not been explored yet. METHOD: Four-week-old male heterozygous TGRs and their normotensive controls--Hannover Sprague-Dawley (HanSD) rats--were fed high-salt diet (2% NaCl) and were treated with selective ETA receptor blocker atrasentan (5 mg/kg per day) for 8 weeks. At the end of the study, the contribution of principle vasoactive systems was evaluated by the sequential blockade of the renin-angiotensin system (captopril), sympathetic nervous system (pentolinium) and nitric oxide synthase [N-nitro-L-arginine methyl ester (L-NAME)]. The role of calcium influx through L-type voltage-dependent calcium channels in BP maintenance was evaluated using nifedipine. In a separate group of animals, the efficiency of distinct vasodilator systems--prostanoids (blocked by nonselective cyclooxygenase inhibitor indomethacin) and Ca-activated K channels (inhibited by tetraethylammonium)--was also analyzed. RESULTS: Atrasentan attenuated the development of hypertension in heterozygous TGRs, but had no effects in Hannover Sprague-Dawley rats. Moreover, atrasentan moderately attenuated renin-angiotensin system-dependent vasoconstriction, whereas it had no effect on sympathetic vasoconstriction. The nifedipine-sensitive BP component was markedly decreased by atrasentan treatment. In contrast, vasodilatation mediated by nitric oxide, endogenous prostanoids or Ca-activated K channels was reduced in atrasentan-treated TGRs, indicating the absence of compensatory augmentation of endothelin B receptor-mediated vasodilation in these animals. CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.
Citace poskytuje Crossref.org
Altered Balance between Vasoconstrictor and Vasodilator Systems in Experimental Hypertension